(Q34270274)

1 August 2017

Adjuvant treatment of GIST: patient selection and treatment strategies (English)

1 reference

1 August 2017

1 reference

Heikki Joensuu

1

1 reference

PubMed ID

22525709

1 August 2017

language of work or name

English

0 references

publication date

24 April 2012

1 reference

Nature Reviews Clinical Oncology

1 August 2017

1 reference

1 August 2017

9

1 reference

1 August 2017

6

1 reference

1 August 2017

351-358

1 reference

https://scigraph.springernature.com/pub.10.1038/nrclinonc.2012.74

1 August 2017

0 references

cites work

Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

NF1-associated gastrointestinal stromal tumors have unique clinical, phenotypic, and genotypic characteristics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney Triad): natural history, adrenocortical component, and possible familial occurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

PDGFRA activating mutations in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

An evaluation of 2537 gastrointestinal stromal tumors for a proposed clinical staging system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

An enhanced risk-group stratification system for more practical prognostication of clinically malignant gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Gastrointestinal stromal tumors in Iceland, 1990-2003: the icelandic GIST study, a population-based incidence and pathologic risk stratification study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

A whole population study of gastrointestinal stromal tumors in the Czech Republic and Slovakia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Gastrointestinal stromal tumors: pathology and prognosis at different sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Risk stratification of patients diagnosed with gastrointestinal stromal tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Predicting recurrence-free survival after surgery for GIST.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Adjuvant and neoadjuvant imatinib therapy: current role in the management of gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

KRAS-mutation positive, metastatic tonsil carcinoma with cancer stem-like cell features and long-term response to gefitinib: a case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

The risks of radiation exposure related to diagnostic imaging and how to minimise them.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Kitlow stem cells cause resistance to Kit/platelet-derived growth factor alpha inhibitors in murine gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Imatinib treatment of metastatic GIST: don't stop (believing).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Gastrointestinal stromal tumours: origin and molecular oncology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Systematic review of escalated imatinib doses compared with sunitinib or best supportive care, for the treatment of people with unresectable/metastatic gastrointestinal stromal tumours whose disease has progressed on the standard imatinib dose

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Risk Criteria and Prognostic Factors for Predicting Recurrences After Resection of Primary Gastrointestinal Stromal Tumor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Mutations in gastrointestinal stromal tumors--a population-based study from Northern Norway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

KIT and PDGFRalpha mutations in 104 patients with gastrointestinal stromal tumors (GISTs): a population-based study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Diagnosis of gastrointestinal stromal tumors: A consensus approach

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Gastrointestinal Stromal Tumors, Intramural Leiomyomas, and Leiomyosarcomas in the Duodenum: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 167 Cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: a clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour – The impact of tumour rupture on patient outcomes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Adjuvant therapy with imatinib mesylate after resection of primary high-risk gastrointestinal stromal tumors in Japanese patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Adjuvant imatinib treatment after R0 resection for patients with high-risk gastrointestinal stromal tumors: a median follow-up of 44 months

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Surgical outcomes of gastrointestinal stromal tumors of the stomach: a single unit experience in the era of targeted drug therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Surgical resection of gastrointestinal stromal tumors after treatment with imatinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.74

Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22525709

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Epidemiology and molecular biology of gastrointestinal stromal tumors (GISTs): a population-based study in the South of Switzerland, 1999-2005.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22525709

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCLINONC.2012.74

1 reference

PubMed ID

22525709

Dimensions Publication ID

1 August 2017

0 references

1 reference

PubMed ID

22525709